177Lu-PSMA-617 radioligand therapy in patient with metastasized castration-resistant prostate cancer: Report of a case and review of the literature

被引：0

作者：

Turpin, L. ^{[1
]}

Calzada, M. C. ^{[1
]}

Yin, J. Zhang ^{[1
]}

Rusu, T. ^{[2
]}

Bruzek, A. Dumont ^{[2
]}

Aveline, C. ^{[1
]}

Sgard, B. ^{[1
]}

Nataf, V. ^{[1
]}

Cussenot, O. ^{[3
]}

Montravers, F. ^{[1
]}

Talbot, J. N. ^{[1
]}

Gauthe, M. ^{[1
,4
]}

机构：

[1] Sorbonne Univ, Hop Tenon, AP HP, Serv Med Nucl, 4 Rue Chine, F-75020 Paris, France

[2] Hop Univ Est Parisien, AP HP, Unite Radiopharm, Pharm Usage Interieur, 4 Rue Chine, F-75020 Paris, France

[3] Sorbonne Univ, Hop Tenon, AP HP, Serv Urol, 4 Rue Chine, F-75020 Paris, France

[4] AP HP, INSERM, UMR 1123, Unite Rech Clin Econ Sante Ile De France, 1 Pl Parvis Notre Dame, F-75004 Paris, France

来源：

MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2019年 / 43卷 / 03期

关键词：

Radioligand therapy; PSMA; Castration-resistant prostate cancer; Lutetium-177; MEMBRANE ANTIGEN; RADIONUCLIDE THERAPY; PET/CT; PREDICTORS; EXPRESSION; EXPERIENCE; DOSIMETRY; LIGAND; SAFETY;

D O I：

10.1016/j.mednuc.2019.03.002

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The prostate-specific membrane antigen (PSMA) is a type II glycoprotein which is over-expressed in prostate cancer tissue, especially in high grade tumours, metastatic disease, as an effect of androgen deprivation therapies and in castrate-resistant prostate cancer (CRPC). Recent studies about radioligand therapy using PSMA ligands labeled with lutetium-177 (Lu-177) in CRPC patients have suggested its interest as a third line of treatment after second generation anti-androgens and chemotherapy by taxane. We present the case of a CRPC patient who was treated by iterative radioligand therapy using PSMA-617 ligand labeled with Lu-177. This case illustrates on the one hand the efficacy of the treatment, and on the other hand the fragility of the patients who are at an advanced stage of their disease. Then we present a short review of the literature on this topic, focusing on the published efficacy and tolerance of Lu-177-PSMA radioligand therapy of CRPC patients. (C) 2019 Elsevier Masson SAS. All rights reserved.

引用

页码：298 / 303

页数：6

共 34 条

[1] The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].

Afshar-Oromieh, Ali ;

Hetzheim, Henrik ;

Kratochwil, Clemens ;

Benesova, Martina ;

Eder, Matthias ;

Neels, Oliver C. ;

Eisenhut, Michael ;

Kuebler, Wolfgang ;

Holland-Letz, Tim ;

Giesel, Frederik L. ;

Mier, Walter ;

Kopka, Klaus ;

Haberkorn, Uwe .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705

[2] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy [J].

Ahmadzadehfar, Hojjat ;

Schlolaut, Stephan ;

Fimmers, Rolf ;

Yordanova, Anna ;

Hirzebruch, Stefan ;

Schlenkhoff, Carl ;

Gaertner, Florian C. ;

Awang, Zool Hilmi ;

Hauser, Stefan ;

Essler, Markus .

ONCOTARGET, 2017, 8 (61) :103108-103116

[3] Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms [J].

Baccala, Angelo ;

Sercia, Linda ;

Li, Jianbo ;

Heston, Warren ;

Zhou, Ming .

UROLOGY, 2007, 70 (02) :385-390

[4]

Balogova S, 2014, CLIN NUCL MED, V39, P951, DOI 10.1097/RLU.0000000000000562

[5] 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].

Baum, Richard P. ;

Kulkarni, Harshad R. ;

Schuchardt, Christiane ;

Singh, Aviral ;

Wirtz, Martina ;

Wiessalla, Stefan ;

Schottelius, Margret ;

Mueller, Dirk ;

Klette, Ingo ;

Wester, Hans-Juergen .

JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013

[6]

Bouchelouche K, 2010, DISCOV MED, V9, P55

[7] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer [J].

Braeuer, Axel ;

Grubert, Lena Sophie ;

Roll, Wolfgang ;

Schrader, Andres Jan ;

Schaefers, Michael ;

Boegemann, Martin ;

Rahbar, Kambiz .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) :1663-1670

[8] Prostate cancer [J].

Brenot-Rossi, I ;

Salaun, P. Y. .

MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2019, 43 (01) :77-84

[9] EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer [J].

Cornford, Philip ;

Bellmunt, Joaquim ;

Bolla, Michel ;

Briers, Erik ;

De Santis, Maria ;

Gross, Tobias ;

Henry, Ann M. ;

Joniau, Steven ;

Lam, Thomas B. ;

Mason, Malcolm D. ;

van der Poel, Henk G. ;

van der Kwast, Theo H. ;

Rouviere, Olivier ;

Wiegel, Thomas ;

Mottet, Nicolas .

EUROPEAN UROLOGY, 2017, 71 (04) :630-642

[10] Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer [J].

Delker, Andreas ;

Fendler, Wolfgang Peter ;

Kratochwil, Clemens ;

Brunegraf, Anika ;

Gosewisch, Astrid ;

Gildehaus, Franz Josef ;

Tritschler, Stefan ;

Stief, Christian Georg ;

Kopka, Klaus ;

Haberkorn, Uwe ;

Bartenstein, Peter ;

Boening, Guido .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (01) :42-51

← 1 2 3 4 →